Park JW - Search Results

1

Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.

Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R. Park JW, et al. J Clin Oncol. 2007 Aug 20;25(24):3680-7. doi: 10.1200/JCO.2006.10.5718. J Clin Oncol. 2007. PMID: 17704416 Clinical Trial.

2

MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer.

Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N. Esserman L, et al. Ann Surg Oncol. 2001 Jul;8(6):549-59. doi: 10.1007/s10434-001-0549-8. Ann Surg Oncol. 2001. PMID: 11456056

3

Tumor targeting using anti-her2 immunoliposomes.

Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC. Park JW, et al. J Control Release. 2001 Jul 6;74(1-3):95-113. doi: 10.1016/s0168-3659(01)00315-7. J Control Release. 2001. PMID: 11489487

4

Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. Park JW, et al. Clin Cancer Res. 2002 Apr;8(4):1172-81. Clin Cancer Res. 2002. PMID: 11948130

5

Liposome-based drug delivery in breast cancer treatment.

Park JW. Park JW. Breast Cancer Res. 2002;4(3):95-9. doi: 10.1186/bcr432. Epub 2002 Apr 18. Breast Cancer Res. 2002. PMID: 12052251 Free PMC article. Review.

6

Immune dysfunction and micrometastases in women with breast cancer.

Campbell MJ, Scott J, Maecker HT, Park JW, Esserman LJ. Campbell MJ, et al. Among authors: park jw. Breast Cancer Res Treat. 2005 May;91(2):163-71. doi: 10.1007/s10549-004-7048-0. Breast Cancer Res Treat. 2005. PMID: 15868444

7

Brain metastases of breast cancer.

Melisko ME, Kunwar S, Prados M, Berger MS, Park JW. Melisko ME, et al. Among authors: park jw. Expert Rev Anticancer Ther. 2005 Apr;5(2):253-68. doi: 10.1586/14737140.5.2.253. Expert Rev Anticancer Ther. 2005. PMID: 15877523 Review.

8

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.

Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. Rugo HS, et al. Among authors: park jw. J Clin Oncol. 2005 Aug 20;23(24):5474-83. doi: 10.1200/JCO.2005.04.192. Epub 2005 Jul 18. J Clin Oncol. 2005. PMID: 16027439 Clinical Trial.

9

A role for biomarkers in the screening and diagnosis of breast cancer in younger women.

Esserman LJ, Shieh Y, Park JW, Ozanne EM. Esserman LJ, et al. Among authors: park jw. Expert Rev Mol Diagn. 2007 Sep;7(5):533-44. doi: 10.1586/14737159.7.5.533. Expert Rev Mol Diagn. 2007. PMID: 17892362 Review.

10

Unraveling the biologic and clinical complexities of HER2.

Park JW, Neve RM, Szollosi J, Benz CC. Park JW, et al. Clin Breast Cancer. 2008 Oct;8(5):392-401. doi: 10.3816/CBC.2008.n.047. Clin Breast Cancer. 2008. PMID: 18952552 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,080 results

Search Page

Filters